173 results
8-K
EX-10.1
OCUP
Ocuphire Pharma Inc
17 Apr 24
Departure of Directors or Certain Officers
4:23pm
team regarding the clinical strategy;
Advising on matters related to the development and design of clinical study protocols and related trial documents
424B3
OCUP
Ocuphire Pharma Inc
16 Feb 24
Prospectus supplement
4:31pm
contained in this prospectus, including statements regarding our future results of operations and financial condition, business strategy and plans … , business strategy and financial needs. These forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions
8-K
EX-99.1
q5tw1dc03
16 Feb 24
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
4:03pm
8-K
8t7v0 cut
5 Dec 23
Departure of Directors or Certain Officers
7:15pm
8-K
EX-99.1
8osvru
2 Nov 23
Ocuphire Corporate Presentation November 2023
8:44am
8-K
EX-99.1
yzwh8mc0
1 Nov 23
Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director
4:21pm
8-K
EX-99.1
q2tadmex9y7ravg
27 Sep 23
RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024
8:45am
424B5
2bimuoeg
14 Aug 23
Prospectus supplement for primary offering
8:00am
8-K
EX-99.1
m7cr5wr2 d9h
1 Aug 23
Restore Vision & Clarity Ocuphire Corporate Presentation August 2023
11:21am
8-K
EX-99.2
ew4zi5q 9g
15 May 23
Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update
8:07am
8-K
EX-99.1
sd0z5wye
21 Apr 23
Ocuphire Appoints Rick Rodgers as Interim Chief Executive Officer
8:10am
8-K
EX-99.1
4tcobk6k
30 Mar 23
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate Update
9:05am
8-K
EX-99.1
2pwzuvrtqjfkrssb
6 Dec 22
Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis
6:37am